Hikma closes NJ facility and tops up supplies from Middle East/North Africa
This article was originally published in Scrip
Executive Summary
The future of Hikma Pharmaceuticals' US generics business is in doubt following its decision to halt production at its Eatontown oral solid dose manufacturing facility in New Jersey after the US FDA said it required additional compliance work. However, Hikma's US customers will continue to be supplied through its FDA-approved manufacturing facilities in the Middle East/North African (MENA) region.